Data as of:
brimindinvest.com / compare / mmm-vs-emrLIVE
MMM
3M Company · Diversified Industrial
$165.89
-8.18% this month
VERSUS
COMPARE
EMR
Emerson Electric Co. · Diversified Industrial Automation
$149.92
-4.87% this month
Comparison scoreboard
EMR LEADS 4/5
AI Scorei
MMM 41.4
EMR 52.3
1Y Returni
MMM +6.75%
EMR +13.65%
Fwd P/Ei
MMM 17.83
EMR 21.42
Target Up.i
MMM +6.44%
EMR +10.72%
Op. Margini
MMM 20.35%
EMR 26.92%
Metrics last refreshed: 9/20/2026
Quick take

MMM vs EMR Stock Comparison: AI Score, Valuation, Performance and Upside

ShareXLinkedInRedditFacebookWhatsApp

MMM and EMR are both industrial conglomerates in transformation. 3M has streamlined by spinning off healthcare (Solventum) while managing significant PFAS and earplug litigation. Emerson has divested climate technology and acquired NI to focus on industrial automation. Emerson's transformation toward software-intensive automation has been better received by the market; 3M's litigation overhang continues to weigh on its valuation despite the Solventum separation.

MMM vs EMR — 3M (the diversified technology company streamlining post-Solventum healthcare spinoff while managing PFAS chemical and combat arms earplug litigation legacy, with patents across adhesives, films, and electronics materials) versus Emerson Electric (the industrial automation specialist refocused on process control, industrial software through AspenTech, and test/measurement through National Instruments acquisition).

Live analysis · updated 9/20/2026

EMR holds the edge across 4 of 5 key metrics in this comparison. EMR has delivered stronger 1-year price return (+13.65% vs +6.75%), though MMM has the better forward P/E setup (17.83x vs 21.42x for EMR). EMR leads on both revenue growth (7.00%) and operating margin (26.92%), suggesting a stronger fundamental setup on both dimensions. Analyst consensus implies meaningfully more upside for EMR (+10.72%) than for MMM (+6.44%).

Normalized 1Y performance
MMM
EMR
Recent returns
MMM
EMR
Analyst price targets & sentiment

Human Wall Street analysts' price targets, typically implying a ~12-month view — a separate signal from this site's own AI Prediction Signal further down the page, which is a 5-/30-day machine-learning forecast based on price history alone.

MMM · 18 analysts
STRONG BUYHOLDSTRONG SELL
Buy (2.2/5.0)
9 Buy / 6 Hold / 3 Sell
Price target range
analyst low$100.00
analyst mean$185.57
current price$165.89
+6.4% upside to analyst mean
EMR
Price target range
analyst mean$171.81
current price$149.92
+10.7% upside to analyst mean
Who should consider this stock?
MMM may suit investors who:
  • see 3M's litigation resolution as eventually clearing the overhang — once PFAS and earplug liabilities are more definitively resolved, the remaining 3M industrial business could rerate higher
  • value Post-it and Scotch's consumer brand durability as reliable consumer revenue across economic cycles alongside the industrial portfolio
  • see Solventum spinoff as unlocking value by giving 3M industrial a separate, cleaner financial identity without healthcare segment complexity
  • are comfortable with ongoing litigation uncertainty, PFAS liability not fully quantified, and the post-Solventum strategic identity transition period
EMR may suit investors who:
  • believe Emerson's transformation toward industrial automation software (AspenTech, NI) creates higher-multiple revenue than the prior diversified hardware-focused business
  • see AspenTech's industrial process optimization software as a high-margin SaaS-like revenue stream embedded in critical industrial operations
  • value Emerson's automation focus as aligned with the decade-long industrial automation capital investment cycle — manufacturers investing in reducing labor and improving efficiency
  • are comfortable with cyclical end market exposure (energy, chemicals), automation competition from Honeywell and Siemens, and strategic transition execution risk during NI integration
Performance & AI score
Performance & AI score
MetricMMMEMR
AI scorei41.452.3
AI ranki#1050#401
Latest closei$165.89$149.92
1M returni-8.18%-4.87%
6M returni+16.24%+15.41%
1Y returni+6.75%+13.65%
$10,000 invested — hypothetical growth (dividends reinvested)

How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?

$10,000 invested — hypothetical growth (dividends reinvested)
PeriodMMMEMR
1Y ago$10.68K (+6.8%)
started 2025-09-18
$11.37K (+13.7%)
started 2025-09-18
5Y ago$14.92K (+49.2%)
started 2021-09-20
$18.62K (+86.2%)
started 2021-09-20
10Y ago$21.28K (+112.8%)
started 2016-09-19
$47.1K (+371.0%)
started 2016-09-19

Hypothetical — past performance does not guarantee future results.

Valuation & upside potential
Valuation & upside potential
MetricMMMEMR
Market capi$89.91B$86.56B
Trailing P/Ei30.9734.03
Forward P/Ei17.8321.42
Price/Salesi3.19N/A
EV/Revenuei3.885.27
Analyst targeti$185.57$171.81
Target upsidei+6.44%+10.72%
Growth, profitability & risk
Growth, profitability & risk
MetricMMMEMR
Revenue growthi2.50%7.00%
Earnings growthi32.80%23.00%
EPS growthi+32.80%+23.00%
FCF margini+25.22%+19.89%
Operating margini20.35%26.92%
Profit margini11.90%13.83%
ROIC proxyi81.89%12.80%
Return on equityi81.89%12.80%
Dividend yieldi1.79%1.43%
Payout ratioi53.64%47.98%
Dividend growth streakiNo increase yetNo increase yet
Betai1.081.24
Debt/equityi437.9467.68
Current ratioi1.240.90
Quick ratioi0.810.62
Correlation

Over the past year, MMM and EMR have moved moderately in the same direction (correlation of 0.45), based on daily returns.

1Y
0.45
-1.0+1.0
5Y
0.49
-1.0+1.0
10Y
0.56
-1.0+1.0
Drawdown & downside risk

Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.

1Y risk snapshot
MMM max drawdowni19.13%
EMR max drawdowni23.74%
MMM max wkly dropi7.99%
EMR max wkly dropi8.22%
5Y risk snapshot
MMM max drawdowni48.86%
EMR max drawdowni29.61%
MMM max wkly dropi13.89%
EMR max wkly dropi15.00%
10Y risk snapshot
MMM max drawdowni59.10%
EMR max drawdowni50.77%
MMM max wkly dropi15.07%
EMR max wkly dropi28.66%
Performance metrics by period
Performance metrics by period
PeriodMetricMMMEMR
1YGrowthi+6.75%+13.65%
CAGRi+6.76%+13.66%
Volatilityi26.24%31.86%
Sharpe ratioi0.210.42
Sortino ratioi0.320.60
Max drawdowni19.13%23.74%
Current drawdowni9.73%8.80%
Avg drawdowni7.37%7.99%
Ulcer Indexi9.22%9.95%
Max daily dropi6.96%6.26%
Max wkly dropi7.99%8.22%
5YGrowthi+27.35%+71.45%
CAGRi+4.96%+11.40%
Volatilityi28.61%27.76%
Sharpe ratioi0.150.37
Sortino ratioi0.240.53
Max drawdowni48.86%29.61%
Current drawdowni9.73%8.80%
Avg drawdowni18.63%8.46%
Ulcer Indexi23.98%10.40%
Max daily dropi11.03%8.65%
Max wkly dropi13.89%15.00%
10YGrowthi+50.94%+266.68%
CAGRi+4.20%+13.88%
Volatilityi26.76%29.28%
Sharpe ratioi0.120.44
Sortino ratioi0.170.62
Max drawdowni59.10%50.77%
Current drawdowni9.73%8.80%
Avg drawdowni23.93%9.23%
Ulcer Indexi28.98%11.96%
Max daily dropi12.95%18.96%
Max wkly dropi15.07%28.66%
AI Prediction Signali
Members only
Next 5 trading days
MMM
+2.8%BUY
EMR
+1.1%HOLD
Next 30 trading days
MMM
+6.4%BUY
EMR
+3.2%HOLD

Sign up to unlock AI price predictions

ML model trained on historical prices · 14-day free trial · No credit card required
Business comparison
Business comparison
CategoryMMMEMR
Company3M CompanyEmerson Electric Co.
SectorIndustrialsIndustrials
IndustryConglomeratesSpecialty Industrial Machinery
Core business3M is a diversified technology company with products across Safety & Industrial (adhesives, personal protective equipment, abrasives), Transportation & Electronics (films, displays, auto parts), Health Care (wound care, dental, filtration), and Consumer (Post-it, Scotch tape, Scotchgard). 3M spun off its healthcare division as Solventum in 2024, focusing the remaining 3M on industrial and electronic products. 3M faces significant legacy litigation from PFAS chemical contamination (military base water contamination, $10.3B settlement) and combat arms earplugs (significant settlements with US veterans). The remaining 3M is streamlining toward automation, advanced materials, and electronics.Emerson Electric is an automation technology company that has strategically streamlined from a diversified industrial conglomerate to focus on industrial automation and process control software/hardware. Emerson sold its Climate Technologies and other non-core businesses and acquired National Instruments (NI, test and measurement) in 2023. Emerson's focus is now on intelligent automation systems (process control, safety systems, industrial software) for energy, chemicals, food and beverage, and life sciences customers. AspenTech (software, Emerson majority ownership) provides AI-powered industrial process optimization.
Investor focusInvestors focus on 3M's litigation resolution progress (PFAS, earplug), Solventum spinoff benefits to remaining 3M, organic revenue growth in the streamlined portfolio, and cost reduction targets.Investors focus on Emerson's automation software and hardware revenue growth, AspenTech integration value, margin expansion from streamlined portfolio, and capital deployment of divestitures proceeds.
MMM strengths
  • Innovation culture with 55,000+ patents: 3M's research and development culture has generated a vast patent portfolio spanning adhesives, films, abrasives, and filtration materials
  • Post-it and Scotch tape consumer brand durability: 3M's consumer brands (Post-it, Scotch) have near-universal brand recognition and consistent demand from office, retail, and home use
  • Electronics and semiconductor materials expertise: 3M's advanced materials (optical films for displays, semiconductor interconnect materials) serve the technology supply chain with specialty products difficult to replace
EMR strengths
  • Automation technology focus for secular demand: industrial automation is a major capital investment priority for manufacturers — Emerson's focus on process control and industrial software positions it for the automation spending cycle
  • AspenTech industrial software exposure: Emerson's majority ownership of AspenTech provides exposure to high-margin industrial process optimization software used in energy, chemicals, and food manufacturing
  • National Instruments (NI) acquisition expanding test and measurement: NI's hardware and software for automated testing complements Emerson's industrial automation focus and adds high-R&D technology customers
Risks to watch — MMM
  • PFAS litigation financial overhang: despite the $10.3B water utility settlement, additional PFAS litigation remains possible — the full financial exposure of 3M's legacy chemical liabilities is uncertain
  • Combat arms earplug settlements: 3M has settled a significant number of veterans' hearing damage claims from defective CAEv2 earplugs — ongoing settlement administration creates cash drain
  • Post-Solventum 3M strategic identity: after spinning off healthcare, 3M must demonstrate that the remaining industrial/electronic business can grow independently without the healthcare division's contribution
Risks to watch — EMR
  • Post-divestiture execution proving the automation-focused story: Emerson must demonstrate that the streamlined automation portfolio can grow faster than the prior diversified business — strategic transitions take time to prove out
  • Automation software competition from Honeywell, Siemens, ABB: Emerson competes in industrial automation with well-resourced global competitors — maintaining technology differentiation vs Honeywell and Siemens requires ongoing R&D investment
  • Cyclical end markets (energy, chemicals): Emerson's process automation customers are in cyclical industries — oil and gas capital spending cycles affect Emerson's order rates and revenue
Frequently asked questions
PFAS (perfluoroalkyl and polyfluoroalkyl substances) are synthetic chemicals used in products like firefighting foam (AFFF), Scotchgard, and non-stick coatings. PFAS have contaminated drinking water sources near military bases and industrial sites globally. 3M was a major PFAS manufacturer. 3M reached a $10.3B settlement in June 2023 with US public water utilities to address PFAS contamination claims — one of the largest environmental settlements in US history. Additional PFAS litigation from states and individuals may create further liability, though the water utility settlement addressed the largest class of plaintiffs.
Free public comparison

Want deeper AI forecasts?

This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.

Related comparisons
More comparisons
Browse all 1,000 comparisons
ShareXLinkedInRedditFacebookWhatsApp